New Horizon for ALK-rearranged NSCLC Patients: lorlatinib
When: Monday, October 27 | 2 p.m. EST
Presenters: Kaiwen Wang, PharmD, BCOP (The University of Texas MD Anderson)
The treatment landscape for metastatic non–small cell lung cancer keeps evolving—and so does the evidence guiding targeted therapy decisions. This session brings together two oncology pharmacists to unpack the latest data and share how these updates translate into real-world care, from efficacy insights to AE management and dose modification.
Kaiwen Wang, PharmD, BCOP, will dive into the latest data and best practices in managing patients receiving lorlatinib for ALK+ metastatic NSCLC. This session reviews long-term survival and intracranial efficacy data, common adverse events, and practical strategies for managing side effects and dose modification to optimize outcomes.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Related Resources
PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC
The purpose of this PQI is to discuss the clinical considerations and general management of encorafenib and binimetinib in non-small cell lung cancer.
August 4, 2025 | 10:51 PM
Additional Upcoming Webinars
Upcoming Webinar
New Horizon for ALK-rearranged NSCLC Patients: lorlatinib
October 27, 2025 | 2:00 PM
Upcoming Webinar
Pharmacy Perspectives: Bringing Bispecifics and 505(b)(2) Medications Into Practice
October 28, 2025 | 5:00 PM




